Hypertension Institute
Nashville, Tennessee, 37205, United States
NCT Number: NCT04529174
Evaluate the effects of a proprietary supplement on total HDL, HDL functionality, HDL particle size and HDL particle number (HDL-P)
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
Nashville, Tennessee, 37205, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Enrollment will occur according to the inclusion/ exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).
Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.
Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.
Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)
Enrollment will occur according to inclusion /exclusion criteria and after the review and signing of the Informed Consent form. Clinical testing will be performed at baseline and each visit (2, 3).
Measurement of height, weight with body composition analysis, body mass index, waist circumference, and vital signs (blood pressure, heart rate) will be measured.
Review of medical history and current medications by clinician; and collection of fasting blood for testing of the complete blood count (CBC), comprehensive metabolic profile (CMP), as well as a urine pregnancy test in females of child-bearing potential.
Visits: Baseline (Visit 1), Week 6 (Visit 2) and Week 12 (Visit 3/End of Study)
Time frame: Change from Baseline to End of Study (week 12)
Reverse Cholesterol Transport (RCT)(CEC) with Cleveland Heart Lab (CHL)
Time frame: Change from Baselineto End of study (week 12)
HDL mapping with Boston Heart Lab (BHL)
Time frame: Change from Baseline to End of Study (week 12)
measured with Quest Lab test
Time frame: Change from Baseline to End of Study (week 12)
Measured with Quest Lab test
Time frame: Change from Baseline to End of Study (week 12)
24 hour recall
Time frame: Change from Baseline to End of Study (week 12)
measured in pounds (Lbs)
Time frame: Change from Baseline to End of Study (week 12)
measured in kg/m2
Time frame: Change from Baseline to End of Study (week 12)
measured in cm
Time frame: Change from Baseline to End of Study (week 12)
measured in mm Hg
Metagenics, Inc.
Industry
Evaluation of an Oral Nutritional Supplement for Effect on Total High-Density Lipoprotein (HDL) Cholesterol, HDL Functionality, Particle Size and Number
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06574711
Apolipoproteins, Behavior
Bogotá, Colombia
View Trial DetailsNCT05641584
Aortic Valve Disease, Aortic Valve Stenosis
Istanbul, Bakırköy, Turkey (Türkiye)
View Trial DetailsNCT03205254
Diet Modification, HDL
Davis, California, United States
View Trial DetailsNCT04330209
Body Weight, Body Weight Changes
View Trial Details